Dirschinger J, Hall D, Rudolph W
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München.
Herz. 1990 Jun;15(3):171-8.
Organic nitrates were the first peripherally-active vasodilators to be used for the treatment of heart failure. Currently, three nitrate derivatives, glycerol trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate as well as the nitrate-like substance molsidomine are employed clinically. For treatment of heart failure, the decisive hemodynamic effect is a meaningful reduction in ventricular filling pressures with maintenance or even a slight increase in cardiac output. The individual response to nitrates is variable. An important indicator for the effect achievable for a certain dose or for the necessary dosage to affect a defined reduction in ventricular filling pressures, is the magnitude of right atrial pressure. It can be assumed that the latter statement is also valid for the nitrate-like substance molsidomine. An inherent problem with any long-term treatment with nitrates is the incurrence of tolerance. This can be expected with any dosing regimen which leads to nitrate cumulation in the plasma or to nearly-constant, high, plasma concentrations as rendered by multiple daily administration of orally-active nitrates or with continuous transdermal or intravenous nitrate administration. The cause of nitrate tolerance is regarded as an insufficient or absent stimulation of guanylate cyclase and, consequently, inadequate generation of cyclic GMP due to availability of thiol substrate. Since the nitrate-like substance molsidomine appears to be able to stimulate guanylate cyclase independent of thiol groups, tolerance development may not be a limiting factor with this agent. Comparable reduction of diastolic pulmonary artery pressure after acute administration and at the end of one week of treatment with 4 mg molsidomine four times daily has been reported.(ABSTRACT TRUNCATED AT 250 WORDS)
有机硝酸盐是最早用于治疗心力衰竭的外周活性血管扩张剂。目前,三种硝酸盐衍生物,即硝酸甘油、二硝酸异山梨酯和5-单硝酸异山梨酯以及类硝酸盐物质莫索尼定在临床上得到应用。对于心力衰竭的治疗,决定性的血流动力学效应是心室充盈压有意义地降低,同时心输出量维持不变甚至略有增加。个体对硝酸盐的反应各不相同。对于某一剂量可达到的效果或影响心室充盈压明确降低所需的剂量而言,一个重要指标是右心房压力的大小。可以假定后一种说法对类硝酸盐物质莫索尼定也成立。硝酸盐长期治疗的一个固有问题是耐受性的产生。任何导致血浆中硝酸盐累积或导致血浆浓度几乎恒定且较高的给药方案都可能出现这种情况,如口服活性硝酸盐每日多次给药或持续经皮或静脉给予硝酸盐。硝酸盐耐受性的原因被认为是鸟苷酸环化酶刺激不足或缺乏,因此,由于硫醇底物的可用性,环磷酸鸟苷生成不足。由于类硝酸盐物质莫索尼定似乎能够独立于硫醇基团刺激鸟苷酸环化酶,耐受性的发展可能不是该药物的限制因素。据报道,每日四次给予4毫克莫索尼定急性给药后及治疗一周结束时,舒张期肺动脉压有类似降低。(摘要截短于250字)